ArticleInternational journal of surgery (London, England)2026
The emerging role of neoadjuvant immunotherapy in locally advanced oral squamous cell carcinoma: progress and challenges.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of locally advanced oral squamous cell carcinoma (LAOSCC) continues to pose significant challenges. Although surgery combined with adjuvant radiotherapy or chemoradiotherapy remains the standard treatment modality, the 5-year overall survival rate for LAOSCC patients is only approximately 50%. Neoadjuvant therapy aims to reduce tumor burden, improve surgical resectability, and decrease distant metastasis risk, yet its clinical value in LAOSCC has not been fully established. In recent years, the remarkable survival benefits demonstrated by immune checkpoint inhibitors in recurrent/metastatic head and neck squamous cell carcinoma have spurred exploration of neoadjuvant immunotherapy (NAIT). However, the efficacy and safety profile of NAIT in LAOSCC still require systematic evaluation. This review synthesizes current evidence and challenges regarding neoadjuvant therapeutic strategies for LAOSCC, encompassing chemotherapy, chemoradiotherapy, targeted therapy, and immunotherapy (as monotherapy or combination regimens), while examining their implications for clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.